Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.52 |
| ▸ | CTSV | O60911 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MDH2 | P40926 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RHEB | Q15382 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727218 | 0.92 | CTSV (0.46) | MAOBCTSVCTSLACHEALDH1A1 | |
| SCHEMBL632222 | 0.86 | CTSV (0.50) | MAOBCTSVCTSLACHEALDH1A1 | |
| SCHEMBL17023377 | 0.78 | MDH2 (0.72) | MAOBCTSVCTSLALDH1A1HPGD | |
| SCHEMBL632016 | 0.77 | MAOB (0.52) | MAOBCTSVCTSLALDH1A1HPGD | |
| SCHEMBL2795363 | 0.76 | CTSV (0.65) | MAOBCTSVCTSLACHEALDH1A1 | |
| SCHEMBL98338 | 0.74 | MAPT (0.54) | MAOBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29498305 | 0.74 | MAPT (0.54) | MAOBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6824331 | 0.74 | MAOB (0.56) | MAOBCTSVCTSLALDH1A1HPGD | |
| SCHEMBL632836 | 0.74 | CTSV (0.50) | MAOBCTSVCTSLACHEALDH1A1 | |
| SCHEMBL7654099 | 0.73 | MAOB (0.79) | MAOBCTSVCTSLACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794154-B1 | HETEROARYL COMPOUNDS FOR USE AS BETAMIMETICS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-1901776-B1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | BOEHRINGER INGELHEIM INT (DE) | 2012-02-22 | — | — | EP | disclosed |
| US-20100297028-A1 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-25 | — | — | US | disclosed |
| US-7632834-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-15 | — | — | US | disclosed |
| EP-1986644-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | Boehringer Ingelheim International GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
| US-7429583-B2 | Betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-30 | — | — | US | disclosed |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOUYSSOU THIERRY | 2008-08-14 | — | — | US | disclosed |
| US-7375104-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| EP-1911749-A1 | New long-working Beta-2 agonists and their use as medicine | Boehringer Ingelheim International GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1901776-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | Boehringer Ingelheim International GmbH (DE) | 2008-03-26 | — | — | EP | disclosed |
| CN-1906180-A | New long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INT (DE) | 2007-01-31 | — | — | CN | disclosed |
| WO-2007003554-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE. | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
| US-7160882-B2 | Long acting β-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-09 | — | — | US | disclosed |
| EP-1711480-A1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2006032627-A1 | HETEROARYL COMPOUNDS FOR USE AS BETAMIMETICS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063817-A1 | New betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-23 | — | — | US | disclosed |
| US-20050277632-A1 | Beta agonists for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110990-A1 | HYDROXY-SUBSTITUTED BENZO-CONDENSED HETEROCYCLES FOR USE AS BETA AGONISTS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| WO-2005070908-A1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | ADRB2, ADRA2A, ADRB1 | MAOB 1193/4885CTSV 2454/4885CTSL 1866/4885 |
| US-20060063817-A1 | New betamimetics for the treatment of respiratory complaints | CHRM1, ADRB1, ADRA1B | MAOB 98/4885CTSV 4074/4885CTSL 1773/4885 |
| US-20050277632-A1 | Beta agonists for the treatment of respiratory diseases | ADRB1, ADRB2, ADRA1B | MAOB 283/4885CTSV 3944/4885CTSL 2556/4885 |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | ADRB2, ADRB1, CHRM1 | MAOB 1288/4885CTSV 2623/4885CTSL 2632/4885 |
| US-20100297028-A1 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | CHRM1, CHRM2, MTNR1B | MAOB 225/4885CTSV 1135/4885CTSL 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.